Summary of clinical studies evaluating FVIII IVR stratified by BMI
Reference . | Study design (age, years) . | n . | Intervention (median IU, range) . | BMI groups (kg/m2) (n) . | IVR (IU dL−1/IU kg−1) . | Strongest predictor of IVR . |
---|---|---|---|---|---|---|
Henrard et al5 | Prospective observational (mean, 40.4 ± 12.3) | 46 | A dose of rFVIII (2000, 980-4200) | 18.5-24.9 (26) 25.0-29.9 (14) ≥30.0 (6) | 1.88 2.30 2.70 | BW |
Henrard et al6 | Retrospective pooled analysis of 8 PK trials (median, 26; IQR, 21-38) | 201 | A dose of rFVIII (3745, 1953-8794) | <18.5 (9) 18.5-24.9 (105) 25.0-29.9 (52) >30.0 (35) | 1.72 2.03 2.18 2.68 | BMI |
Henrard et al7 | Retrospective pool analysis of 6 PK trials (median, 14.5; IQR, 12.8-15.6)a | 66 | A dose of rFVIII (2778, 1675-5420) | Normal (43) Overweight (7) Obese (16)b | 1.93 2.12 2.65 | BMI-for-age |
Tiede et al8 | Prospective observational (mean, 37.4; range, 23.0–57.0) | 35 | rFVIII 50 IU/kg by ABW | <18.5 (5) 18.5-24.9 (7) 25.0-29.9 (9) 30.0-34.9 (7) ≥35 (7) | 2.2c 2.9c 2.9c 3.2c 3.5c | BMI |
Reference . | Study design (age, years) . | n . | Intervention (median IU, range) . | BMI groups (kg/m2) (n) . | IVR (IU dL−1/IU kg−1) . | Strongest predictor of IVR . |
---|---|---|---|---|---|---|
Henrard et al5 | Prospective observational (mean, 40.4 ± 12.3) | 46 | A dose of rFVIII (2000, 980-4200) | 18.5-24.9 (26) 25.0-29.9 (14) ≥30.0 (6) | 1.88 2.30 2.70 | BW |
Henrard et al6 | Retrospective pooled analysis of 8 PK trials (median, 26; IQR, 21-38) | 201 | A dose of rFVIII (3745, 1953-8794) | <18.5 (9) 18.5-24.9 (105) 25.0-29.9 (52) >30.0 (35) | 1.72 2.03 2.18 2.68 | BMI |
Henrard et al7 | Retrospective pool analysis of 6 PK trials (median, 14.5; IQR, 12.8-15.6)a | 66 | A dose of rFVIII (2778, 1675-5420) | Normal (43) Overweight (7) Obese (16)b | 1.93 2.12 2.65 | BMI-for-age |
Tiede et al8 | Prospective observational (mean, 37.4; range, 23.0–57.0) | 35 | rFVIII 50 IU/kg by ABW | <18.5 (5) 18.5-24.9 (7) 25.0-29.9 (9) 30.0-34.9 (7) ≥35 (7) | 2.2c 2.9c 2.9c 3.2c 3.5c | BMI |